Silence Therapeutics plc 8-K

What Happened
Silence Therapeutics plc announced on May 18, 2026 that it entered into a new Open Market Sale AgreementSM with Jefferies LLC to sell American Depositary Shares (ADSs) in an at‑the‑market (ATM) program under its Form S-3 shelf (File No. 333-295992). Each ADS represents three ordinary shares (nominal value £0.05). The new Sales Agreement replaces a prior agreement dated October 15, 2021 (terminated effective May 18, 2026). The company also updated its prior disclosures after further tax analysis and now believes it was not a passive foreign investment company (PFIC) for the tax year ended December 31, 2025.

Key Details

• Agreement date: May 18, 2026; prior agreement (Oct 15, 2021) terminated same day.
• Offering: ATM sales of ADSs through Jefferies, subject to the Registration Statement on Form S-3 (File No. 333-295992) once declared effective.
• Fees and terms: Jefferies may act as agent/principal; company pays up to a 3.0% commission on gross proceeds; Silence is not obligated to sell any ADSs; either party may terminate the Sales Agreement by written notice.
• ADS specifics: each ADS = 3 ordinary shares, nominal value £0.05 per share; maximum program amount referenced in agreement (amount not specified in 8‑K).
• Tax update: after further analysis, Silence believes it should not have been classified as a PFIC for its taxable year ended Dec 31, 2025, but acknowledges no assurance for past, current or future years and that U.S. counsel expresses no opinion. The filing notes potential adverse U.S. tax consequences for U.S. holders if the company is or becomes a PFIC (e.g., loss of preferential rates, interest charges, extra reporting, QEF/mark‑to‑market issues).
• Legal opinion: Opinion of Cooley (UK) LLP regarding ADS validity is filed as Exhibit 5.1.

Why It Matters
The new ATM agreement gives Silence a flexible way to raise capital by selling ADSs into the market over time, but it does not require the company to sell shares and any sales would dilute existing holders. The 3.0% commission and customary indemnities are typical for such programs. The PFIC clarification reduces immediate tax uncertainty for U.S. investors regarding 2025, but the company warns there is no definitive assurance for other years and that U.S. holders should consult tax advisors because PFIC status can carry significant tax and reporting consequences.